A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis

NCT03334435 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1645

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Baricitinib
DRUG: Placebo

Sponsor

Eli Lilly and Company

Collaborators

[object Object]